Kevin R. Sayer

Chairperson of the Board, President, and CEO at Dexcom Inc

Board

Since January 2015

Age

66 years

Education

Holds a Master's Degree in Accounting and Information Systems and a B.A. from Brigham Young University.

Tenure

Joined DexCom in November 2007, served as President from 2011, as COO from January 2013 to January 2015, and has been CEO since January 2015 with appointment as Chairperson in July 2018.

Also at Dexcom Inc

JSL

Jacob S. Leach

Executive Vice President and COO

JMS

Jereme M. Sylvain

Executive Vice President and CFO

Matthew Dolan

Executive Vice President of Strategy, Corporate Development & Dexcom Labs

About

Kevin R. Sayer is a seasoned executive in the healthcare and medical technology industries, known for his extensive expertise in financial management and operational strategy.

He began his journey at DexCom in November 2007 and has held several key roles, progressing from serving on the Board to assuming positions as President, COO, and ultimately CEO, where his leadership has significantly influenced the company’s strategic growth.

Before his tenure at DexCom, he built a robust career with financial leadership roles, including positions as CFO at Biosensors International Group and MiniMed, as well as serving as an independent consultant and an executive at Specialty Laboratories. His diverse experience underscores his ability to navigate complex financial environments in the evolving medical technology landscape.

$DXCM Performance Under Kevin R. Sayer

Past Roles

Organization	Role	Date Range	Details
Dexcom	Chief Operating Officer	January 2013 - January 2015	Served as COO before transitioning to CEO and Chairperson roles
Biosensors International Group, Ltd.	Chief Financial Officer	April 2007 - December 2010	Medical technology company developing, manufacturing, and commercializing devices used in interventional cardiology and critical care procedures
Independent Consultant	Healthcare and Medical Technology Industry Consultant	May 2005 - April 2007	Provided consulting services in the healthcare and medical technology industries
Specialty Laboratories, Inc.	Executive Vice President & Chief Financial Officer	March 2004 - May 2005	Provided clinical reference laboratory services
Independent Consultant	Healthcare and Medical Technology Industry Consultant	August 2002 - March 2004	Provided consulting services in the healthcare and medical technology industries
Medtronic MiniMed	Vice President and General Manager	August 2001 - August 2002	Held this role following Medtronic's acquisition of MiniMed
MiniMed, Inc.	Chief Financial Officer	May 1994 - August 2001	Company later acquired by Medtronic, leading to subsequent roles at Medtronic MiniMed

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,092,822	Prorated for 2023	16% increase from 2022 base salary (from $965,000 to $1,120,000)
Perquisites or Personal Benefits	$128,255	One-time in 2023	Includes $112,716 for personal security arrangements and $15,539 for spouse-related taxable event
Reimbursement of Taxes Owed	$15,280	One-time in 2023	Tax gross-up related to spouse’s awards ceremony expenses

Performance Compensation

Data from FY 2023

Non-Equity Incentive Plan Compensation

Metric	Value	Details
Target Annual Bonus %	130%	Applied to Base Salary
Threshold Payout	$710,334	50% of the target payout opportunity
Target Payout	$1,420,669	100% of the target payout opportunity
Maximum Payout	$2,841,337	200% of the target payout opportunity
Actual Bonus Paid	$1,988,948	Exceeded target due to the application of financial and individual performance multipliers
Performance Multipliers	Financial & Individual	Financial multiplier based on Adjusted Revenue, Non-GAAP Operating Margin, and CEO Strategic Initiatives; Individual multiplier ranges from 0% to 200% as determined by the Compensation Committee

2023 Performance Stock Units (PSUs)

Metric	Value	Details
Corporate Performance Metrics	Minimum: <$3.22B, Target: $3.37B, Maximum: $3.62B	Adjusted Revenue thresholds with multipliers of 0%, 100%, and 160%; achieved performance at 157% of target
Relative TSR Performance Period	3 years	From January 1, 2023 to December 31, 2025; performance measured against the Nasdaq Composite Index
PSU Grant Date	March 9, 2023
Grant Date Fair Value	$6,728,682
Number of PSUs Granted	Threshold: 10,885, Target: 54,422, Maximum: 108,844	Based on achieving performance metrics
Potential Payout Range	Achieved approximately 85,585 to 106,981	Determined by the combined Corporate Performance Multiplier and Relative TSR Multiplier
Vesting Schedule	Certification Dates	Corporate metric vests in Q1 2024; Relative TSR metric vests in Q1 2026, contingent on continued employment through certification